Stocks Health care PRME
NASDAQ · Health carePrime Medicine, Inc. (PRME)
It posted a net loss of $187.9M. In fiscal 2025 capital spending exceeded operating cash flow by $167.1M. At June 30, 2026 it held $47.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about Prime Medicine, Inc.
- Net worth
- Prime Medicine, Inc. has a market value (market cap) of $707.4M at the latest share price, and shareholders' equity of $39.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $4.6M (+55.3% year on year), with a net loss of $201.1M.
- Cash flow
- In fiscal 2025 operations used $162.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Prime Medicine, Inc.'s next report was expected around November 6, 2026 and is not on file with the SEC yet.
What Prime Medicine, Inc. does
Prime Medicine, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker PRME.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $4.6M | -$201.1M | -$1.35 | -$167.1M |
| 2024 | $3M | -$195.9M | -$1.65 | -$130.2M |
| 2023 | $0 | -$198.1M | -$2.18 | -$174.1M |
| 2022 | $0 | -$121.8M | -$4.19 | -$147.9M |
| 2022 | $0 | -$165.4M | -$14.19 | -$38.2M |
| 2020 | $5.2M | -$3.4M | -$1.91 | -$6.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where PRME ranks in Health care
Latest SEC filings
What Prime Medicine, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 6, 2026
- August 6, 2026
- July 8, 2026Other event 8-K
- June 8, 2026
- May 7, 2026
- May 7, 2026
- April 23, 2026
- April 23, 2026Additional proxy material DEFA14A
- April 23, 2026Proxy statement DEF 14A
- April 16, 2026
Insider trades
What the people running Prime Medicine, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns PRME
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Alphabet Holdings LLC13G, passive with 11 related filers | 12.3% | November 12, 2025 |
| Robert Nelsen13D, may seek influence with 11 related filers | 10.4% | August 11, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 187 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Alphabet Inc. | 16,562,498 | 0 |
| BlackRock, Inc. | 9,602,041 | +1,100,333 |
| ARK Investment Management LLC | 8,348,746 | +2,101,919 |
| State Street Corp | 7,576,460 | +1,231,335 |
| Vanguard Capital Management LLC | 4,522,640 | +48,478 |
| Balyasny Asset Management L.P. | 3,969,082 | -154,283 |
| Goldman Sachs Group Inc | 3,430,518 | +2,460,093 |
| Casdin Capital, LLC | 3,167,175 | 0 |
| Woodline Partners LP | 3,003,904 | +591 |
| UBS Group AG | 2,794,689 | -93,729 |
| Geode Capital Management, LLC | 2,712,446 | -31,254 |
| Sumitomo Mitsui Trust Group, Inc. | 2,412,984 | -527,809 |
| Amova Asset Management Americas, Inc. | 2,407,018 | -533,775 |
| Citadel Advisors LLC | 2,054,543 | +1,718,185 |
| ADAR1 Capital Management, LLC | 1,997,552 | +24,270 |
| Fmr LLC | 1,761,884 | -7,592 |
| Two Sigma Investments, LP | 1,524,511 | -48,300 |
| Redmile Group, LLC | 1,389,632 | -201,200 |
| Farallon Capital Management, L.L.C. | 1,240,843 | 0 |
| Jump Financial, LLC | 1,240,429 | new |
Insiders
Questions about PRME
What does Prime Medicine, Inc. do?
Prime Medicine, Inc. is a company in the Health care sector, listed on NASDAQ as PRME. Its shares trade on NASDAQ under the ticker PRME.
What is Prime Medicine, Inc.'s net worth?
Prime Medicine, Inc. has a market value (market cap) of $707.4M at the latest share price, and shareholders' equity of $39.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Prime Medicine, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $187.9M.
When did Prime Medicine, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026.
When is Prime Medicine, Inc.'s next earnings report?
Prime Medicine, Inc.'s next report was expected around November 6, 2026 and is not on file with the SEC yet.
Similar companies
Compare PRME with
Follow PRME
Get an email when Prime Medicine, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Prime Medicine, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.